E.E. Geduld’s Rigel Pharmaceuticals RIGL Stock Holding History

E.E. Geduld’s Portfolio RIGL Stock Details RIGL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q1	–	Sell	-1,000	Closed	-$30K	–	193
2015 Q4	$30K	Sell	1,000 -500	-33%	-$15.2K	0.02%	151
2015 Q3	$37K	Sell	1,500 -1,000	-40%	-$29.8K	0.03%	162
2015 Q2	$80K	Hold	2,500	–	–	0.05%	220
2015 Q1	$89K	Buy	+2,500	New	+$68.5K	0.06%	202

Other funds holding RIGL

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

OppenheimerFunds New York $80.4B AUM 15.1% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

E.E. Geduld's RIGL Position: Q1 2016 in Review

E.E. Geduld sold out of Rigel Pharmaceuticals (RIGL) in Q1 2016, closing a stake of 1,000 shares — an estimated $30K sold.

E.E. Geduld first reported a position in RIGL in Q1 2015 and held it in 4 quarters. The position peaked at $89K in Q1 2015. 120 funds tracked by Wall St. Rank hold RIGL as of Q1 2016.

E.E. Geduld reported no remaining Rigel Pharmaceuticals position as of Q1 2016 after selling out during the quarter.
E.E. Geduld sold 1,000 Rigel Pharmaceuticals shares in Q1 2016, an estimated $30K.
E.E. Geduld first reported a position in Rigel Pharmaceuticals in Q1 2015 and held it in 4 quarters.
E.E. Geduld's Rigel Pharmaceuticals position peaked at $89K in Q1 2015.
120 funds tracked by Wall St. Rank held Rigel Pharmaceuticals as of Q1 2016.

Based on E.E. Geduld's 13F filing for Q1 2016, filed 9 May 2016.